Table 2.
Factors related to 1-year mortality ratio in patients with AAV according to univariate regression and multivariate regression.
| Univariate regression | Multivariate regression | |||
|---|---|---|---|---|
| OR | P-value | OR [95%CI] | P-value | |
| Basic features | ||||
| Gender(M/F) | 5.01 | 0.025* | 5.41 [1.19-24.59] | 0.029* |
| Age | 4.78 | 0.096 | ||
| Course of disease | 2.76 | 0.096 | ||
| Classification of diseases | ||||
| GPA | 0.20 | 0.652 | ||
| MPA | 0.00 | 0.978 | ||
| EGPA | 0.16 | 0.689 | ||
| Types of ANCA | ||||
| p-ANCA | 0.13 | 0.719 | ||
| c-ANCA | 0.01 | 0.92 | ||
| MPO | 0.36 | 0.548 | ||
| PR3 | 0.00 | 0.978 | ||
| Organ involvement | ||||
| Lung | 1.27 | 0.684 | ||
| Kidney | 2.33 | 0.124 | ||
| Skin | 2.56 | 0.442 | ||
| Mucosa and eye | 0.00 | 1.000 | ||
| Ear, nose, throat | 0.35 | 0.401 | ||
| Cardiovascular | 0.67 | 1.00 | ||
| Nervous system | 0.00 | 0.999 | ||
| Joint and muscle | 1.67 | 0.367 | ||
| Non-specific symptoms | 1.49 | 0.53 | ||
| Laboratory indicators | ||||
| WBC | 14.63 | 0.000* | 2.35 [0.46–11.88] | 0.303 |
| HB | 1.19 | 0.276 | ||
| PLT | 6.32 | 0.012* | 7.00 [1.42–34.57] | 0.017* |
| N | 14.64 | 0.000* | 2.35 [0.46–11.88] | 0.303 |
| L | 0.58 | 0.448 | ||
| NLR | 7.03 | 0.008* | 15.87 [1.48–170.15] | 0.022* |
| PLR | 0.00 | 0.984 | ||
| MPV | 10.72 | 0.001* | 2.28 [0.38-13.55] | 0.367 |
| RDW-CV | 4.26 | 0.039* | 3.27 [1.14–9.38] | 0.028* |
| RDW-SD | 16.86 | 0.000* | 2.73 [0.29–25.92] | 0.383 |
| ESR | 1.72 | 0.19 | ||
| CRP | 10.72 | 0.001* | 2.28 [0.38–13.55] | 0.367 |
| C3 | 1.62 | 0.204 | ||
| C4 | 0.33 | 0.567 | ||
| ALT | 2.93 | 0.087 | ||
| ALB | 0.08 | 0.773 | ||
| GLB | 3.46 | 0.063 | ||
| TBIL | 6.07 | 0.014* | 2.86 [0.77–10.67] | 0.117 |
| Scr | 5.61 | 0.018* | 4.67 [1.10–19.92] | 0.037* |
| BUN | 28.61 | 0.000* | 5.17 [0.27–99.91] | 0.277 |
| UA | 5.85 | 0.016* | 1.85 [0.48–7.09] | 0.372 |
| Albuminuria | 3.87 | 0.049* | 0.35 [0.12–1.05] | 0.062 |
| Hematuria | 0.12 | 0.727 | ||
| BVAS | 5.26 | 0.022* | 1.57 [0.50–4.97] | 0.444 |
| Treatment after diagnosis | ||||
| Different doses of GC | ||||
| <0.5mg/kg | 0.396 | 0.529 | ||
| 0.5–1mg/kg | 0.417 | 0.518 | ||
| >1kg/mg | 0.166 | 0.684 | ||
| CTX | 2.012 | 0.156 | ||
| MMF | 0.192 | 0.661 | ||
| Plasma exchange | 0.386 | 0.535 | ||
| CD20 monoclonal antibody | 0.404 | 0.525 | ||
| Single drug or combination drugs | ||||
| 1 drug | 0.98 | 0.323 | ||
| 2 drugs | 4.441 | 0.035* | 3.38 [0.73–15.67] | 0.12 |
| 3 drugs | 1.232 | 0.267 | ||
| ≥4 drugs | 0.672 | 0.412 | ||
M/F, Males/Females; OR, Odds ratio; CI, Confidence interval; GPA, Granulomatous vasculitis; MPA, Microscopic vasculitis; EGPA, Eosinophilic granulomatous polyangiitis; c-ANCA, Cytoplasmic anti-neutrophil cytoplasmic antibody; p-ANCA, Perinuclear anti-neutrophilic cytoplasmic antibody; PR3, Protease 3; MPO, Myeloperoxidase; WBC, White blood cell; HB, Hemoglobin; PLT, Platelet; N, Neutrophils; L, Lymphocytes; NLR, Neutrophil-lymphocyte ratio; PLR, Platelet lymphocyte ratio; MPV, Mean platelet volume; RDW-CV, Red blood cell volume width-variation of red blood cells; RDW-SD, Red blood cell volume distribution width-standard deviation; ESR, Erythrocyte sedimentation; CRP, C-reactive protein; C3, Complement 3; C4: Complement 4; ALT, Glutamic-pyruvic transaminase; ALB, Albumin; GLO, Globulin; TBIL, Total bilirubin; BUN, Urea nitrogen; Scr, Serum creatinine; UA, Uric acid; BVAS, Birmingham Vasculitis Activity Score; GC, Glucocorticoid; CTX, Cyclophosphamide; MMF, Mycophenolate mofetil;
P < 0.05.